Skip to Main Content
This site is intended for healthcare professionals View Patient/Caregiver Site Important Safety Information Full Prescribing Information
DYANAVEL XR Logo

ADHD Innovation

Innovative technology provides consistent drug delivery and predictable symptom control from patient to patient through the day 1-3

IR complexes come into contact with positively charged exchange ions from gastrointestinal fluid, displacing ions and releasing medication 2

ER complexes have coatings of variable thickness that enable a controlled release of medication through diffusion and ion exchange 2

How Tris ADHD LiquiXR Technology Works Illustration

Our technology puts your patient first

Drug releases slowly throughout the day and is not affected by:4,5

  • Timing or type of food consumed
  • pH of the GI tract
  • Location of release in GI tract
  • Amphetamine or methylphenidate metabolism

See how it works

Unique Technology is at the core of all Tris ADHD products

Tris Pharma offers amphetamine and methylphenidate treatment options for patients 6 years and older with ADHD.

Select a product below.

DYANAVEL XR Tablet amphetamine extended-release tablets 5mg, 10mg, 15mg, 20mg Logo Once Daily Dyanavel XR extended release
Tris Once-Daily ADHD Tablet Amphetamine Tablet Icon
Once-daily tablet amphetamine
Learn more about
DYANAVEL XR tablet
DYANAVEL XR Liquid amphetamine extended-release oral suspension 2.5 mg/mL Logo/mL Logo #1 Dyanavel XR extended release oral suspension
Tris Once-Daily ADHD Liquid Amphetamine Droplet Icon
Once-daily liquid amphetamine
Learn more about
DYANAVEL XR liquid
QuilliChew ER methylphenidate HCl for extended-release chewable tablets 20mg, 30mg, 40mg Logo #1 QuilliChew ER, the only once-daily extended-release methylphenidate tablet
Tris Once-Daily ADHD Tablet Methylphenidate Tablet Icon
Once-daily tablet methylphenidate
Learn more about
QuilliChew ER
Quillivant XR methylphenidate HCl for extended-release oral suspension 25mg/5mL Logo #1 Quillivant XR, the first once-daily, long-acting* liquid methylphenidate treatment
Tris Once-Daily ADHD Liquid Methylphenidate Droplet Icon
Once-daily liquid methylphenidate
Learn more about
Quillivant XR
Help Your Patients Save On Tris ADHD Products Money Sign Icon

Help your patients save on Tris ADHD products.

ADHD, Attention Deficit Hyperactivity Disorder; ER, extended-release; IR, immediate-release; pH, potential of hydrogen.

References: 1. Kando JC, King TR, Pardo A. A novel, modified-release drug delivery technology containing amphetamine and methylphenidate ion-exchange complexes. Poster presented at: American Psychiatric Association Annual Meeting; May 1-3, 2021. 2. Cutler AJ, Pardo A, King TR, et al. Randomized, double-blind, placebo-controlled, fixed-dose study to evaluate the efficacy and safety of the amphetamine extended-release tablet in adults with attention-deficit/hyperactivity disorder. Poster presented at 2021 APSARD; January 15-17. 3. Childress AC, Wigal SB, Brams MN, et al. Efficacy and safety of amphetamine extended-release oral suspension in children with attention-deficit/hyperactivity disorder. J Child Adolesc Psycholpharmacol. 2018;28(5):306-313. 4. Herman BK, King TR, Kando JC, et al. A novel, modified release drug delivery technology (LiquiXR®) containing amphetamine ion-exchange complexes. Poster presented at: Psych Congress; October 3-6, 2019. San Diego, CA. 5. Powell JJ, Greenfield SM, Thompson RP. Concentrations of metals in gastric juice in health and peptic ulcer disease. Gut. 1992;33(12):1617-1620.

IMPORTANT SAFETY INFORMATION

isi open close button

WARNING: ABUSE AND DEPENDENCE

CNS stimulants, including Dyanavel XR, Quillivant XR, QuilliChew ER, and other amphetamine-containing or methylphenidate-containing products, have a high potential for abuse and dependence. Assess the risk of abuse prior to prescribing and monitor for signs of abuse and dependence while on therapy.

IMPORTANT SAFETY INFORMATION

WARNING: ABUSE AND DEPENDENCE

CNS stimulants, including Dyanavel XR, Quillivant XR, QuilliChew ER, and other amphetamine-containing or methylphenidate-containing products, have a high potential for abuse and dependence. Assess the risk of abuse prior to prescribing and monitor for signs of abuse and dependence while on therapy.

  • Dyanavel XR (amphetamine), Quillivant XR (methylphenidate HCl), and QuilliChew ER (methylphenidate HCl) are contraindicated:
    • in patients known to be hypersensitive to amphetamine, methylphenidate, or other components of Dyanavel XR, Quillivant XR, and QuilliChew ER. Hypersensitivity reactions, such as angioedema and anaphylactic reactions, have been reported.
    • in patients taking monoamine oxidase inhibitors (MAOIs), or within 14 days of stopping MAOIs, because of risk of hypertensive crisis.
  • Avoid use in patients with known structural cardiac abnormalities, cardiomyopathy, serious cardiac arrhythmias, coronary artery disease, and other serious cardiac problems. Sudden death, stroke, and myocardial infarction have been reported in adults treated with CNS stimulants at recommended doses. Sudden death has been reported in pediatric patients with structural cardiac abnormalities and other serious cardiac problems when taking CNS stimulants at recommended doses for ADHD. Further evaluate patients who develop exertional chest pain, unexplained syncope, or arrhythmias during treatment with Dyanavel XR, Quillivant XR, and QuilliChew ER.
  • CNS stimulants cause increase in blood pressure (mean increase approximately 2 to 4 mm Hg) and heart rate (mean increase about 3 to 6 bpm). Monitor all patients for tachycardia and hypertension.
  • CNS stimulants may exacerbate symptoms of behavior disturbance and thought disorder in patients with a preexisting psychotic disorder. They may induce a mixed/manic episode in patients with bipolar disorder. Assess for presence of bipolar disorder prior to initiating treatment. At recommended doses, stimulants may cause psychotic or manic symptoms, e.g., hallucinations, delusional thinking, or mania, in patients without prior history of psychotic illness or mania. If such symptoms occur, consider discontinuing Dyanavel XR, Quillivant XR, or QuilliChew ER.
  • CNS stimulants have been associated with weight loss and slowing of growth rate in pediatric patients with ADHD; monitor weight and height during treatment with Dyanavel XR, Quillivant XR, and QuilliChew ER. Treatment may need to be interrupted in children not growing or gaining weight as expected.
  • CNS stimulants are associated with peripheral vasculopathy, including Raynaud's phenomenon. Signs and symptoms are usually intermittent and mild; very rare sequelae include digital ulceration and/or soft tissue breakdown. Careful observation for digital changes is necessary during treatment with ADHD stimulants.
  • Cases of painful and prolonged penile erections and priapism have been reported with methylphenidate products. Immediate medical attention should be sought if signs or symptoms of prolonged penile erections or priapism are observed.
  • Serotonin syndrome risk is increased when Dyanavel XR is co-administered with serotonergic agents (e.g., SSRIs, SNRIs, triptans), MAOIs, and during overdosage situations. If it occurs, discontinue Dyanavel XR and any concomitant serotonergic agents immediately, and initiate supportive treatment.
  • QuilliChew ER contains phenylalanine, a component of aspartame, and can be harmful to patients with phenylketonuria (PKU).
  • Most common adverse reactions observed with amphetamine products: dry mouth, anorexia, weight loss, abdominal pain, nausea, insomnia, restlessness, emotional lability, dizziness, and tachycardia.
  • Based on limited experience with Dyanavel XR in controlled trials, the adverse reaction profile of Dyanavel XR appears similar to other amphetamine extended-release products. The most common (≥2% in the Dyanavel XR group and greater than placebo) adverse reactions reported in the Phase 3 controlled study conducted in 108 patients with ADHD (aged 6 to 12 years) were: epistaxis (Dyanavel XR 4%, placebo 0%), allergic rhinitis (4%, 0%) and upper abdominal pain (4%, 2%).
  • Based on accumulated data from other methylphenidate products, the most common (≥5% and twice the rate of placebo) adverse reactions are: appetite decreased, insomnia, nausea, vomiting, dyspepsia, abdominal pain, weight decreased, anxiety, dizziness, irritability, affect lability, tachycardia, blood pressure increased.
  • There is limited experience with Quillivant XR and QuilliChew ER in controlled trials.
    • Quillivant XR: The most common (≥2% in the Quillivant XR group and greater than placebo) adverse reactions reported in the Phase 3 controlled study conducted in 45 ADHD patients (ages 6 to 12 years) in Quillivant XR compared to placebo were affect lability (9% Quillivant XR, 2% placebo), excoriation (4%, 0%), initial insomnia (2%, 0%), tic (2%, 0%), decreased appetite (2%, 0%), vomiting (2%, 0%), motion sickness (2%, 0%), eye pain (2%, 0%), and rash (2%, 0%).
    • QuilliChew ER: The most common (≥2% in the QuilliChew ER group and greater than placebo) adverse reactions reported in the Phase 3 controlled study conducted in 90 pediatric subjects (ages 6 to 12 years) in QuilliChew ER compared to placebo were decreased appetite (2.4% QuilliChew ER, 0% placebo), aggression (2.4%, 0%), emotional poverty (2.4%, 0%), nausea (2.4%, 0%), headache (2.4%, 0%), and weight decreased (2.4%, 0%).
  • Dyanavel XR, Quillivant XR, and QuilliChew ER use during pregnancy may cause fetal harm.
  • Breastfeeding is not recommended during treatment with Dyanavel XR, Quillivant XR, or QuilliChew ER.

INDICATION

Dyanavel XR, Quillivant XR, and QuilliChew ER are indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in patients 6 years and older.

See Full Prescribing Information for Dyanavel XR, Quillivant XR, and QuilliChew ER, including Boxed Warning regarding Abuse and Dependence.

This site is intended for healthcare professionals in the United States, its territories, and Puerto Rico.